Losartan and Testosterone Interaction: What Patients and Clinicians Need to Know

How Each Drug Works: A Quick Pharmacology Primer

Before assessing what happens when these two agents share a patient, each drug's mechanism needs to be clear. Losartan blocks the angiotensin II type-1 (AT1) receptor, reducing vasoconstriction and aldosterone release, which lowers blood pressure and provides renal protection in diabetic nephropathy. Testosterone, whether delivered as cypionate, enanthate, or a topical gel, binds androgen receptors in muscle, bone, and the kidneys, triggering erythropoiesis, sodium retention, and changes in lipid metabolism.

Losartan's Pharmacokinetic Profile

Losartan is a prodrug converted by CYP2C9 to its active carboxylic acid metabolite, EXP-3174, which is roughly 10 to 40 times more potent at the AT1 receptor than the parent compound. CYP3A4 handles a secondary metabolic pathway. The FDA label for losartan (Cozaar) documents this clearly, noting that CYP2C9 poor metabolizers show higher losartan exposure and lower EXP-3174 exposure, potentially altering both efficacy and side-effect burden [1].

Testosterone's Pharmacokinetic Profile

Exogenous testosterone is metabolized primarily by CYP3A4, with additional involvement of CYP2C9 for some hydroxylation steps. Testosterone cypionate given intramuscularly at 100 mg weekly produces peak serum testosterone levels of roughly 700 to 1,100 ng/dL at 24 to 48 hours post-injection, falling toward 400 to 600 ng/dL by day 7 [2]. This weekly oscillation in androgen levels means that blood pressure is not a fixed target: it can shift measurably between injection days.

The Pharmacokinetic Interaction: CYP2C9 Overlap

The most clinically discussed pharmacokinetic angle is the shared CYP2C9 pathway. Both losartan (conversion to EXP-3174) and testosterone (partial hydroxylation) use this enzyme. At standard clinical doses, competition for CYP2C9 binding is considered minor because testosterone's affinity for CYP2C9 is substantially lower than that of strong inhibitors like fluconazole.

What the Evidence Actually Shows

A 2005 interaction study published in the British Journal of Clinical Pharmacology found that co-administration of fluconazole, a potent CYP2C9 inhibitor, raised losartan AUC by approximately 50% and reduced EXP-3174 AUC by 73%, producing a meaningful drop in antihypertensive effect [3]. Testosterone is not a potent CYP2C9 inhibitor, so the magnitude of interaction via this route is far smaller than what fluconazole produces.

Genetic CYP2C9 poor metabolizers (roughly 3 to 5% of European-ancestry populations) already have impaired conversion of losartan to EXP-3174 [4]. Adding testosterone's modest CYP2C9 competition in this subgroup could theoretically blunt losartan efficacy further. Clinicians prescribing the combination in patients with known CYP2C9 *2 or *3 alleles should monitor blood pressure response closely rather than assuming standard dosing is adequate.

P-glycoprotein: A Secondary Consideration

Both compounds interact weakly with P-glycoprotein (Pgp), the efflux transporter encoded by ABCB1. The clinical significance of Pgp overlap at physiological concentrations of both drugs is not established in prospective trials. It represents a theoretical rather than documented concern at this time.

The Pharmacodynamic Interactions: Where the Real Risk Lives

Pharmacodynamic interactions are the ones that matter most day-to-day in clinical practice. These arise not from competing for the same enzyme, but from each drug pushing a physiological variable in directions that affect the other's targets.

Blood Pressure: Opposing Forces That Don't Always Balance

Losartan at doses of 50 to 100 mg daily typically reduces systolic blood pressure by 10 to 15 mmHg in patients with stage 1 hypertension [5]. Testosterone's effect on blood pressure is more complex and dose-dependent. Supraphysiological testosterone (above 1,000 ng/dL) promotes sodium retention via renal mineralocorticoid-like effects and stimulates sympathetic nervous system activity, both of which push systolic pressure upward. Within physiological replacement ranges (400 to 700 ng/dL), the effect is modest, but it is not zero.

A meta-analysis of 19 randomized controlled trials (N=1,084) published in the Journal of Hypertension found that testosterone therapy produced a mean systolic blood pressure reduction of 2.0 mmHg (95% CI: 0.6 to 3.4) in hypogonadal men, primarily attributed to improved endothelial function and reduced vascular resistance at physiological concentrations [6]. The key phrase is physiological concentrations. When TRT is dosed aggressively and troughs remain high, that modest benefit can reverse.

The clinical implication: losartan's antihypertensive effect may be sufficient when testosterone is held in the 400 to 700 ng/dL trough range, but physicians should check home blood pressure readings around injection days to catch the early-week spikes.

Hematocrit and Polycythemia: The Most Actionable Risk

Testosterone stimulates erythropoiesis by increasing erythropoietin production and directly acting on erythroid progenitors in bone marrow [7]. Hematocrit rises predictably with TRT, typically reaching its new steady-state 3 to 6 months after therapy begins.

The Endocrine Society 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest that clinicians measure hematocrit at baseline, at 3 to 6 months, and then annually. We recommend against initiating testosterone therapy if the hematocrit is greater than 54%." [8]

When hematocrit exceeds 52 to 54%, blood viscosity increases, raising the risk of thromboembolic events. Losartan does not lower hematocrit. It does not antagonize erythropoiesis. A patient with hypertension managed on losartan who develops polycythemia from TRT carries a compounded cardiovascular risk: elevated blood viscosity plus residual hypertension if losartan titration has not kept pace with the testosterone-driven changes.

HealthRX Hematocrit Action Framework for Patients on Losartan + TRT:

| Hematocrit Value | Action | |---|---| | <52% | Continue current TRT dose; monitor every 3 months | | 52 to 54% | Reduce TRT dose or extend injection interval; recheck in 6 weeks | | >54% | Hold TRT; evaluate for therapeutic phlebotomy; reassess losartan dose if BP has risen | | >58% persistent | Consider discontinuing TRT; hematology referral |

Lipid Panel Changes: HDL, LDL, and the Losartan Offset

Testosterone therapy, particularly injectable forms, suppresses HDL cholesterol. The suppression is dose-dependent: in a 52-week trial of testosterone undecanoate (N=237), HDL fell by a mean of 5.7 mg/dL from baseline [9]. LDL changes are more variable, ranging from modest reductions to no change, depending on baseline body composition and aromatization rate.

Losartan itself has minimal direct lipid effects. Its renal protective and cardiovascular benefits in the LIFE trial (N=9,193) were not attributable to lipid modulation but to superior AT1 receptor blockade and reduction of left ventricular hypertrophy regression compared with atenolol [10]. Still, if a patient's lipid panel deteriorates on TRT, adding a statin becomes relevant, and the physician should not assume losartan is covering lipid risk.

Renal Considerations: Two Drugs, One Set of Kidneys

Losartan is prescribed specifically because it slows progression of diabetic nephropathy. The RENAAL trial (N=1,513) showed that losartan 50 to 100 mg daily reduced the risk of a doubling of serum creatinine by 25% and end-stage renal disease by 28% over a mean follow-up of 3.4 years in patients with type 2 diabetes and proteinuria [11].

Testosterone and Renal Function: A Nuanced Picture

Testosterone's renal effects are less consistently studied. Some data suggest that androgens promote sodium and water retention via the renal tubule, increasing glomerular filtration pressure. In patients with diabetic nephropathy already at risk for hyperfiltration injury, this retention effect could theoretically offset part of losartan's renal protection. No large randomized trial has demonstrated that TRT worsens renal outcomes in men using ARBs. The concern is physiologically plausible rather than definitively established.

Patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73m² should have a more detailed risk-benefit discussion before starting TRT alongside losartan, and creatinine and potassium should be monitored more frequently, at minimum every 3 months.

Potassium: The Quiet Variable

Losartan raises serum potassium by reducing aldosterone-driven potassium excretion. Testosterone at physiological doses has minimal direct effect on potassium. However, if TRT causes significant muscle mass gain with concurrent dietary protein increases (and thus higher potassium intake), potassium can drift upward in patients on ARBs. Hyperkalemia above 5.5 mEq/L warrants a repeat check and dietary review before any dose adjustment.

Cardiovascular Risk: Reading the Full Picture

The combination of TRT and an ARB exists in a patient population that already carries elevated cardiovascular risk. Hypogonadism itself is associated with metabolic syndrome, increased visceral adiposity, and insulin resistance, all of which drive cardiovascular disease independently.

What the Testosterone Cardiovascular Trials Say

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men 45 to 80 years old with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo over a mean follow-up of 33 months (HR 0.96, 95% CI: 0.78 to 1.17) [12]. The TRAVERSE trial did show a statistically significant increase in pulmonary embolism (PE) in the testosterone group (0.9% vs. 0.5%, P<0.05) and atrial fibrillation (3.5% vs. 2.4%, P<0.001).

These PE and atrial fibrillation findings underscore why hematocrit management is not optional. Losartan does not reduce PE risk. If hematocrit rises unchecked in a patient on both drugs, the thromboembolic signal from TRAVERSE becomes a real concern rather than a statistical abstraction.

The Blood Pressure Variability Problem

Blood pressure variability, not just mean blood pressure, is an independent predictor of stroke and cardiovascular events. A pooled analysis of 389,000 participants in PROGRESS, ADVANCE, and other trials found that visit-to-visit systolic BP variability was associated with a 25% higher risk of stroke per standard deviation increase [13]. Weekly injectable testosterone creates predictable peaks and troughs in androgen levels, and with it, oscillating blood pressure. Losartan's once-daily dosing smooths out much of this variability at the pharmacological level, but home BP monitoring around the injection peak remains a reasonable clinical practice.

Drug Interactions with Losartan: Broader Context

Losartan has several well-documented interactions beyond testosterone that clinicians should keep in mind when managing these patients.

CYP2C9 Inhibitors and Inducers

Strong CYP2C9 inhibitors, including fluconazole, amiodarone, and miconazole, can substantially reduce conversion of losartan to EXP-3174, blunting its antihypertensive and nephroprotective effect [3]. Strong CYP2C9 inducers like rifampin accelerate losartan conversion and may increase EXP-3174 exposure. Men on TRT who are also receiving azole antifungals (sometimes used for androgenic alopecia-related regimens) face a compounded interaction risk worth flagging.

NSAIDs and the Renal Triple Whammy

Co-prescribing NSAIDs (ibuprofen, naproxen) with losartan and any diuretic creates the well-known triple whammy interaction: acute kidney injury risk rises substantially [14]. Men on TRT occasionally take NSAIDs for musculoskeletal pain. They should be counseled to prefer acetaminophen for pain management and to contact their provider before using NSAIDs for more than a few days.

Potassium-Sparing Agents

Adding potassium-sparing diuretics (spironolactone, eplerenone) or potassium supplements to a losartan regimen risks hyperkalemia. Spironolactone is occasionally used in men with TRT-related water retention, though its anti-androgenic properties make it a poor choice in this context.

Patient Counseling: What to Tell Someone Starting This Combination

Clear, direct patient education reduces both under-treatment and self-discontinuation. Men often stop losartan because they feel well without connecting the medication to blood pressure control, and they may stop TRT prematurely if they attribute new symptoms to testosterone without proper attribution.

The Five Key Messages

1. Take your losartan every day. Missing doses on TRT is more consequential than missing doses without it, because testosterone's sodium-retaining effect is ongoing.

2. Check your blood pressure at home. Aim for readings twice weekly, once on the day of injection and once before your next injection. Write them down.

3. Get your blood drawn on schedule. The 3-month CBC is not optional. Hematocrit above 52% means a conversation with your doctor before the next injection.

4. Report these symptoms immediately: shortness of breath, leg swelling, chest pain, or severe headache. These may indicate either uncontrolled blood pressure or a clotting event.

5. Avoid ibuprofen and naproxen for routine aches. Acetaminophen is the preferred option while you are on an ARB.

Monitoring Protocol: A Structured Timeline

The Endocrine Society's 2018 guideline [8] provides the scaffold, and the FDA prescribing information for Cozaar (losartan) adds renal and electrolyte checkpoints [1].

Baseline (Before Starting TRT)

• Serum testosterone (total and free), LH, FSH, SHBG
• CBC with differential (hematocrit, hemoglobin)
• Comprehensive metabolic panel (creatinine, potassium, eGFR, liver enzymes)
• Fasting lipid panel
• PSA
• Blood pressure (in-office and at-home average)
• Body weight and BMI

Month 3

• Serum total testosterone (trough, morning, before injection)
• Hematocrit and hemoglobin
• Blood pressure (in-office)
• Symptom review: erythrocytosis symptoms, edema, mood

Month 6

• Full repeat of baseline labs
• Adjust losartan dose if systolic BP remains above 130 mmHg at trough (pre-injection) readings
• Adjust TRT dose or interval if hematocrit exceeds 52%

Month 12 and Annually Thereafter (if stable)

• Full repeat of baseline labs
• Bone mineral density if patient is over 50 or has osteoporosis risk factors
• Cardiovascular risk assessment using ACC/AHA pooled cohort equations

Special Populations

Men with Type 2 Diabetes

This population is the most likely to be on losartan (for diabetic nephropathy) and among the most likely to be hypogonadal. The prevalence of hypogonadism in men with type 2 diabetes is approximately 25 to 40% [15]. Managing both conditions simultaneously requires especially tight renal monitoring, given that losartan's nephroprotective mechanism can be compromised by testosterone-driven sodium retention and the hemodynamic stress of elevated hematocrit.

Older Men (Age >65)

The TRAVERSE trial enrolled men 45 to 80 years old [12], and older men with hypertension are common candidates for this drug combination. Age-related decline in renal clearance means that potassium accumulation on losartan is more likely. Starting TRT at a lower dose (50 to 75 mg testosterone cypionate weekly rather than 100 mg) and titrating up based on trough levels reduces the hematocrit overshoot risk in this group.

Men with Baseline Hematocrit >48%

The Endocrine Society guideline recommends caution before starting TRT when baseline hematocrit already sits above 48% [8]. In a patient on losartan with pre-existing borderline erythrocytosis, the risk of crossing the 54% threshold within 3 to 6 months of TRT initiation is substantially higher. A lower-dose or transdermal TRT formulation (gel produces smaller hematocrit increases than injectable preparations) should be the default starting choice.